GANX Key Statistics, Chart & Performance
The current stock price of GANX is 3.755 USD. In the past month the price increased by 102.63%. In the past year, price increased by 115.08%.
GANX Latest News, Press Relases and Analysis
GANX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 14.9 | 175.47B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 150.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 74.60B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 876.47 | 59.05B | ||
| INSM | INSMED INC | N/A | 43.52B | ||
| NTRA | NATERA INC | N/A | 33.78B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.84B | ||
| INCY | INCYTE CORP | 15.14 | 19.08B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About GANX
Company Profile
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Company Info
GAIN THERAPEUTICS INC
4800 Montgomery Lane, Suite 220
Bethesda MARYLAND 20814 US
CEO: Eric Richman
Employees: 24
Phone: 13015001556
GAIN THERAPEUTICS INC / GANX FAQ
Can you describe the business of GAIN THERAPEUTICS INC?
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
What is the current price of GANX stock?
The current stock price of GANX is 3.755 USD. The price decreased by -2.47% in the last trading session.
What is the dividend status of GAIN THERAPEUTICS INC?
GANX does not pay a dividend.
What is the ChartMill rating of GAIN THERAPEUTICS INC stock?
GANX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting GANX stock to perform?
11 analysts have analysed GANX and the average price target is 6.94 USD. This implies a price increase of 84.71% is expected in the next year compared to the current price of 3.755.
What is the employee count for GANX stock?
GAIN THERAPEUTICS INC (GANX) currently has 24 employees.
GANX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GANX. When comparing the yearly performance of all stocks, GANX is one of the better performing stocks in the market, outperforming 97.63% of all stocks.
GANX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GANX. The financial health of GANX is average, but there are quite some concerns on its profitability.
GANX Financial Highlights
Over the last trailing twelve months GANX reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 47.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.36% | ||
| ROE | -278.1% | ||
| Debt/Equity | 0.04 |
GANX Forecast & Estimates
11 analysts have analysed GANX and the average price target is 6.94 USD. This implies a price increase of 84.71% is expected in the next year compared to the current price of 3.755.